Passionflower Sleep Randomized Trial: What the Evidence Says

Quick Answer

Passionflower Sleep Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Although these products are available without a prescription and are generally thought to be safe, there are pharmacological and toxicological risks associated with their use. [Căuș Maria-Nina (2026); evidence level 3]
• The differences in the regulatory framework allow for broad consumer access to plant-based products; it also creates potential gaps in safety monitoring and risk communication. [Căuș Maria-Nina (2026); evidence level 3]
• These disturbances occur despite adequate opportunity and conditions for sleep, and they result in general dissatisfaction with sleep quality and various daytime impairments. [Żełabowski Kacper (2025); evidence level 3]
• Individuals reporting nighttime symptoms without associated daytime dysfunction are not classified as having clinical insomnia. [Żełabowski Kacper (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For passionflower sleep randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Căuș Maria-Nina (2026). Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. DOI: 10.3390/ph19030399. PMCID: PMC13028908. PMID: 41901246. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13028908/
• Żełabowski Kacper (2025). The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs. DOI: 10.3390/molecules30183814. PMCID: PMC12472680. PMID: 41011705. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12472680/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.